Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma

This phase I trial tests the safety, side effects and best dose of azacitidine in combination with belinostat and how well the combination works in treating patients with follicular helper T cell lymphoma (TFH) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). This phase I trial also tests the safety, side effects and best dose of pralatrexate in combination with belinostat and how well the combination works in treating patients with relapsed or refractory peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CT

Trial Details

NCT ID
NCT07691450
Phase
PHASE1
Sponsor
City of Hope Medical Center
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Azacitidine
  • Belinostat
  • Biospecimen Collection
  • Computed Tomography
  • FDG-Positron Emission Tomography
  • Fludeoxyglucose F-18
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Newnan, Georgia, United States|33.38067,-84.79966

Key Eligibility Criteria

  • Ability to understand and willingness to sign a written informed consent document
  • Documented informed consent of the participant and/or legally authorized representative. Assent, when appropriate, will be obtained per institution…
  • Age: ≥ 18 years
  • Have a performance status of 0-1 on the Eastern Cooperative Oncology Group (ECOG) Scale (performance status \[PS\]) at time of enrollment. Patients…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →